{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:17:08Z","timestamp":1790169428989,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today: Technologies"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ddtec.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:58:16Z","timestamp":1544057896000},"page":"71-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?"],"prefix":"10.1016","volume":"30","author":[{"given":"Paul J.M.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-3188","authenticated-orcid":false,"given":"Syafiq","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Pysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ddtec.2018.10.004_bib0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody\u2013drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-018-0302-5","article-title":"Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody\u2013drug conjugates","volume":"32","author":"Khera","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0020","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/ja00952a050","article-title":"Isolation and characterization of anthramycin, a new antitumour antibiotic","volume":"87","author":"Leimgruber","year":"1965","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0025","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1021\/ja01022a078","article-title":"Total synthesis of anthramycin","volume":"90","author":"Leimgruber","year":"1968","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0030","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0005-2787(74)90372-4","article-title":"The reaction of anthramycin with DNA II. Studies of kinetics and mechanism","volume":"361","author":"Kohn","year":"1974","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0035","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0022-2836(70)90008-2","article-title":"Reaction of anthramycin with deoxyribonucleic acid","volume":"51","author":"Kohn","year":"1970","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0040","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1016\/S0021-9258(20)65126-2","article-title":"Reaction of anthramycin with DNA biological consequences of DNA damage in normal and xeroderma pigmentosum cell","volume":"257","author":"Petrusek","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0045","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/bi00084a043","article-title":"Correlation of DNA sequence specificity of anthramycin and tomaymycin with reaction kinetics and bending of DNA","volume":"32","author":"Kizu","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0050","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/cr100120f","article-title":"Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)","volume":"111","author":"Antonow","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152009787047743","article-title":"Pyrrolo[2 1-c][1,4]benzodiazepines as a scaffold for the design and synthesis of anti-tumour drugs","volume":"9","author":"Cipolla","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0060","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/med.20212","article-title":"Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines","volume":"32","author":"Gerratana","year":"2012","journal-title":"Med Res Rev"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/cr00026a006","article-title":"Synthesis of DNA-interactive pyrrolo[2 1-c][1,4]benzodiazepines","volume":"94","author":"Thurston","year":"1994","journal-title":"Chem Rev"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0070","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1016\/S0040-4039(00)80691-7","article-title":"Synthesis and dna crosslinking ability of a dimeric anthramycin analog","volume":"29","author":"Farmer","year":"1988","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0075","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1021\/ja00038a089","article-title":"Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system","volume":"114","author":"Bose","year":"1992","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0080","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/jm001064n","article-title":"Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity","volume":"44","author":"Gregson","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0085","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0090","doi-asserted-by":"crossref","first-page":"13756","DOI":"10.1021\/ja902986x","article-title":"The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links","volume":"131","author":"Rahman","year":"2009","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0095","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/ja00952a050","article-title":"Isolation and characterization of anthramycin, a new antitumor antibiotic","volume":"87","author":"Leimgruber","year":"1965","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7164\/antibiotics.25.437","article-title":"Studies on tomaymycin, a new antibiotic. I. Isolation and properties of tomaymycin","volume":"25","author":"Arima","year":"1972","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0105","first-page":"308","article-title":"Antitumor effect of a new antibiotic, neothramycin","volume":"71","author":"Hisamatsu","year":"1980","journal-title":"Gann"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0110","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7164\/antibiotics.25.668","article-title":"Sibiromycin: isolation and characterization","volume":"25","author":"Brazhnikova","year":"1972","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0115","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1078-0432.CCR-08-1315","article-title":"Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors","volume":"15","author":"Hochhauser","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0120","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","article-title":"A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors","volume":"65","author":"Janjigian","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0125","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-10-2056","article-title":"Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors","volume":"17","author":"Puzanov","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0135","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","author":"Phillips","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0140","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1124\/dmd.116.073031","article-title":"Antibody drug conjugates differentiate uptake and DNA alkylation of pyrrolobenzodiazepines in tumors and organs of xenograft mice","volume":"44","author":"Ma","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0150","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) yargeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"10479","key":"10.1016\/j.ddtec.2018.10.004_bib0155","first-page":"1","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0160","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/1538-7445.AM2018-736","article-title":"Abstract 736: pyridinobenzodiazepines (PDDs): a new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity","volume":"78","author":"Veillard","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0165","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","article-title":"CLT030, a leukemic stem cell\u2013targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia","volume":"2","author":"Jiang","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acsmedchemlett.7b00436","article-title":"Design and synthesis of isoquinolidinobenzodiazepine dimers, a novel class of antibody\u2013drug conjugate payload","volume":"9","author":"Smith","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0175","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A new class of antibody-drug conjugates with potent DNA alkylating activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0180","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.V124.21.2321.2321","article-title":"The antibody-drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against acute myeloid leukemia (AML) with FLT3-ITD mutations","volume":"124","author":"Whiteman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0185","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","article-title":"IMGN779, a novel CD33-targeting antibody\u2013drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0190","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-Targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0195","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1074\/jbc.RA118.002545","article-title":"Cryo-EM structure of a mammalian RNA polymerase II elongation complex inhibited by alpha-amanitin","volume":"293","author":"Liu","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0200","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0205","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab Ozogamicin: first global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1026234130830","article-title":"BR96\u2013DOX immunoconjugate targeting of chemotherapy in brain tumor models","volume":"65","author":"Muldoon","year":"2003","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0215","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-trop-2\/SN-38 antibody\u2013drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0220","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1093\/nar\/gkr122","article-title":"Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers","volume":"39","author":"Rahman","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0225","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody\u2013drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0230","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood.V128.22.2832.2832","article-title":"IMGN632: A CD123-targeting antibody-drug conjugate (ADC) with a novel DNA-alkylating payload, is highly active and prolongs survival in acute myeloid leukemia (AML) xenograft models","volume":"128","author":"Adams","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0235","unstructured":"https:\/\/news.abbvie.com\/news\/abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-rova-t-for-third-line-treatment-patients-with-dll3-expressing-relapsedrefractory-small-cell-lung-cancer.htm. [Accessed 7th September 2018] AbbVie announces results from phase 2 study evaluating rovalpituzumab tesirine (Rova-T) for third-line treatment of patients with DLL3-expressing relapsed\/refractory small cell lung cancer."},{"key":"10.1016\/j.ddtec.2018.10.004_bib0240","article-title":"Rova-T delivers disappointing results in phase II SCLC trial","author":"Harris","year":"2018","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0245","first-page":"1312","article-title":"IMGN779, a next-generation CD33-targeting antibody-drug conjugate (ADC) demonstrates initial antileukemia activity in patients with relapsed or refractory acute myeloid leukemia","volume":"130","author":"Cortes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0250","series-title":"22nd Congress of the European hematology association (EHA)","author":"Miller","year":"2017"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0255","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2018.36.15_suppl.8507","article-title":"Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing,\u2009\u2265\u20093rd line small cell lung cancer: results from the phase 2 TRINITY study","volume":"36","author":"Carbone","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0260","first-page":"1510","article-title":"Interim results from a phase 1 study of ADCT-301 (Camidanlumab Tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed\/refractory hodgkin\/non-hodgkin lymphoma","volume":"130","author":"Horwitz","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hon.2437_33","article-title":"First clinical results of ADCT-402, a novel pyrrolobenzodiazepine-based antibody drug conjugate (ADC), in relapsed\/refactory B-Cell lineage NHL","author":"Kahl","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0270","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2018.36.15_suppl.1014","article-title":"A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer","volume":"36","author":"Saura","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0275","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/bi102017e","article-title":"Nuclear magnetic resonance solution structures of inter- and intrastrand adducts of DNA cross-linker SJG-136","volume":"50","author":"Hopton","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0280","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/bi0479813","article-title":"Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies","volume":"44","author":"Martin","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0285","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-17-0697","article-title":"Intratumoral payload concentration correlates with the activity of antibody\u2013drug conjugates","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0290","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1124\/dmd.116.073031","article-title":"Antibody drug conjugates differentiate uptake and DNA alkylation of pyrrolobenzodiazepines in tumors from organs of xenograft mice","volume":"44","author":"Ma","year":"2016","journal-title":"Drug Metabo Dispos"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0295","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1074-5521(00)00010-7","article-title":"Alteration in the choice of DNA repair pathway with increasing sequence selective DNA alkylation in the minor groove","volume":"7","author":"Brooks","year":"2000","journal-title":"Chem Biol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0300","doi-asserted-by":"crossref","first-page":"23465","DOI":"10.1074\/jbc.272.38.23465","article-title":"Nucleotide excision repair in mammalian cells","volume":"272","author":"Wood","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0305","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0027-5107(00)00037-3","article-title":"Nucleotide excision repair in yeast","volume":"451","author":"Prakash","year":"2000","journal-title":"Mutat Res Fundam Mol Mech Mutagen"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0310","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(01)00454-5","article-title":"Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance","volume":"2","author":"McHugh","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0315","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1158\/0008-5472.CAN-03-2941","article-title":"SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity","volume":"64","author":"Hartley","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0320","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjc.6603853","article-title":"Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells","volume":"97","author":"Pepper","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0325","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/1538-7445.AM2015-946","article-title":"Abstract 946: SGN-CD70A, a pyrrolobenzodiazepine (PBD) dimer linked ADC, mediates DNA damage pathway activation and G2 cell cycle arrest leading to cell death","volume":"75","author":"Sandall","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0330","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1158\/1535-7163.MCT-07-0294","article-title":"DNA sequence selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145","volume":"6","author":"Kiakos","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0335","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0340","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance\u2014Challenges and solutions","volume":"18","author":"Shefet-Carasso","year":"2015","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0345","unstructured":"www.adctherapeutics.com. [Accessed 7th September 2018] ADC Therapeutics announces the termination of its ADCT-502 program targeting HER2 expressing solid tumors."},{"key":"10.1016\/j.ddtec.2018.10.004_bib0350","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0355","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1039\/c0ob00762e","article-title":"Observation of the reversibility of a covalent pyrrolobenzodiazepine (PBD) DNA adduct by HPLC\/MS and CD spectroscopy","volume":"9","author":"Rahman","year":"2011","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0360","doi-asserted-by":"crossref","first-page":"2792A","DOI":"10.1158\/1538-7445.AM2018-2792A","article-title":"Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors","volume":"78","author":"Zammarchi","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0365","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/1538-7445.AM2018-744","article-title":"Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors","volume":"78","author":"Zammarchi","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0370","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","article-title":"Chemoenzymatic conjugation of toxic payloads to the globally conserved N-Glycan of native mAbs provides homogeneous and highly efficacious antibody\u2013drug conjugates","volume":"26","author":"van Geel","year":"2015","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0375","unstructured":"Howard PW, Ezeadi, ED\u2019Hooge F, Patel N, Kemp G. Pyrrolobenzodiazepines and Conjugates Thereof. [2018] (Limited, M., Ed.)."},{"key":"10.1016\/j.ddtec.2018.10.004_bib0380","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS1102","article-title":"A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and\/or metastatic breast cancer previously treated with T-DM1","volume":"36","author":"Baselga","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0385","unstructured":"https:\/\/www.daiichisankyo.com\/media_investors\/media_relations\/press_releases\/detail\/006765.html. [Accessed 7th September 2018] Daiichi Sankyo Presents updated data for DS-8201 in patients with HER2-expressing breast cancer at San Antonio Breast Cancer Symposium"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0390","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/1535-7163.MCT-16-0688","article-title":"Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, site-specific conjugation","volume":"16","author":"Stefan","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0395","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","article-title":"Recent developments in ADC technology: preclinical studies signal future clinical trends","volume":"31","author":"Drake","year":"2017","journal-title":"Biodrugs"},{"key":"10.1016\/j.ddtec.2018.10.004_bib0400","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug\u2013antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody\u2013maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjugate Chemistry"}],"updated-by":[{"DOI":"10.1016\/j.ddtec.2021.01.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000}}],"container-title":["Drug Discovery Today: Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674918300179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674918300179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:21:59Z","timestamp":1761668519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1740674918300179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":80,"alternative-id":["S1740674918300179"],"URL":"https:\/\/doi.org\/10.1016\/j.ddtec.2018.10.004","relation":{},"ISSN":["1740-6749"],"issn-type":[{"value":"1740-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today: Technologies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ddtec.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}